ArticleEuropean journal of case reports in internal medicine2024
Fungal Necrotizing Fasciitis Due to Mucormycosis Following Contaminated Substance Inoculation: A Report of Two Cases.
Article in European journal of case reports in internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Predicting the absence of World Health Organization fungal priority pathogens in agricultural soils using machine learning and ITS metabarcoding.Die Naturwissenschaften · 2026Article
- Survival and renal outcomes of mucormycosis infection and its treatment regimens in resource-limited settings: a retrospective case series.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Fatal Cutaneous Mucormycosis Initially Misdiagnosed as Necrotizing Fasciitis in an Uncontrolled Diabetic Patient: A Case Report Highlighting Diagnostic Delay.International medical case reports journal · 2026Article
- Life-saving hip disarticulation following necrotizing myofasciitis from invasive mucormycosis after blast injury: A case report.International journal of surgery case reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mucormycosis is a life-threatening fungal infection caused by Mucorales fungi, characterized by angioinvasion and tissue necrosis. While it predominantly affects immunocompromised individuals, it can also occur in immunocompetent patients through traumatic inoculations, such as contaminated surgical dressings or injections. We report two cases of cutaneous mucormycosis following the shared use of contaminated intramuscular corticosteroid injections (dexamethasone). Case 1 involved a 54-year-old male farmer with rapidly progressing necrotic lesions and multi-organ failure, resulting in death despite aggressive treatment. Case 2 involved a 48-year-old female nursing technician who developed similar necrotizing lesions and also succumbed to multi-organ failure after extensive debridement and antifungal therapy. These cases underscore the rapid deterioration associated with mucormycosis, an infection with a high mortality rate even in immunocompetent individuals. The hallmark of the disease is rapidly progressing necrosis due to vascular invasion and thrombosis. Mucormycosis following contaminated injections, though rare, is devastating. Early recognition and aggressive treatment, including surgical debridement and antifungal therapy, are critical but may not always prevent fatal outcomes. Strict infection prevention precautions and epidemiological surveillance are needed to prevent iatrogenic infections. LEARNING POINTS: Direct inoculation of Mucorales species through contaminated injections is a rare but serious route of infection, highlighting the importance of proper handling of medical equipment.Mucormycosis can occur in immunocompetent individuals following traumatic events or contaminated procedures, and it often leads to rapid tissue necrosis and high mortality if not promptly treated.Early surgical debridement and antifungal therapy are critical for managing mucormycosis, though survival remains poor even with aggressive intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.